Back to Authors

Bhavsar, Shweta

0000-0003-2408-2154

Mayo Clinic

Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.

Citations 1

Transformation of FL into DLBCL with a PMBL gene expression signature
Loveday, Tristan , Duns, Gerben , Rimsza, Lisa M. , Rech, Karen L. , Cook, James R. , Robetorye, Ryan S. , Ramsower, Colleen , Yip, Tameson, McKinney, Catherine L., Bhavsar, Shweta , Rosenthal, Allison , Ramsower, Colleen A , Yip, Tameson K, Swerdlow, Steven H , Bhavsar, Shweta , Steidl, Christian , Gibson, Sarah E , Rimsza, Lisa M , Rech, Karen , Mckinney, Catherine, Swerdlow, Steven H. , Steidl, Christian , Gibson, Sarah E.

Blood Advances | October 14, 2022 | Volume: 7 | Issue: 6 | Pages: 893-899

10.1182/bloodadvances.2022007360 Get It

Abstract We investigated the clinicopathologic features of 5 follicular lymphomas (FLs) that transformed (tFL) morphologically to diffuse large B-cell lymphomas (DLBCLs) and had a primary mediastinal large B-cell lymphoma (PMBL)–like gene expression profile (tFL-PMBLsig-pos). None of the tFL-PMBLsig-pos cases arose in the mediastinum, all cases tested had a germinal center B-cell phenotype, 20% were CD30+, 60% CD23+, 80% MAL+, 20% CD200+, and 0% CD273/PDL2+. Whole-exome sequencing detected alterations in genes associated with both FL/DLBCL (CREBBP, KMT2C, KMT2D, ARID1A, HIST1 members, and TNFRSF14) and PMBL (JAK-STAT pathway genes, B2M, and CD58). Copy number (CN) analysis detected gains/amplification of REL and STAT6 in 60%, gains of SOCS1 in 40%, and gains of chromosome 16, including IL4R, in 40% of the cases. CN gains/amplification of BCL6 and MYC and loss of TNFRSF14 and TNFAIP3 were identified in 20% of the cases. Three of 5 cases lacked a BCL2 rearrangement. Despite having some features that are less common in DLBCL (MAL and CD23 expression and JAK-STAT activation), these tFL-PMBLsig-pos cases lack the most characteristic CN alteration seen in PMBL (9p24.1 gain/amplification). This cohort expands the biologic heterogeneity of tFL, illustrating a subset with gene expression and some genetic features reminiscent of PMBL, with potential treatment implications that include the use of novel targeted therapies.